Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Testosterone and Alendronate in Hypogonadal Men

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Massachusetts General Hospital
Endo Pharmaceuticals
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Benjamin Leder, MD, Massachusetts General Hospital Identifier:
First received: October 20, 2011
Last updated: June 25, 2014
Last verified: June 2014

This study will investigate the hypothesis that the combination of testosterone replacement and alendronate will improve bone density and parameters of bone quality more than either medication alone in older men with low testosterone levels and low bone density.

Condition Intervention Phase
Drug: Testosterone
Drug: Alendronate
Drug: Placebo Alendronate
Drug: Placebo Testosterone
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Testosterone and Alendronate in Hypogonadal Men

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Spine Bone Mineral Density by DXA [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: October 2011
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Testosterone and Placebo Alendronate Drug: Testosterone
Testosterone Gel (Fortesta) 40mg daily.
Drug: Placebo Alendronate
A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.
Placebo Comparator: Alendronate and Placebo Testosterone Drug: Alendronate
Alendronate (Fosamax) 70mg every week.
Drug: Placebo Testosterone
Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
Experimental: Tesosterone and Alendronate Drug: Testosterone
Testosterone Gel (Fortesta) 40mg daily.
Drug: Alendronate
Alendronate (Fosamax) 70mg every week.


Ages Eligible for Study:   60 Years to 85 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male sex
  • Age 60 or above
  • Testosterone <300 ng/dL
  • DXA T score < -1 OR FRAX Score of 3% or greater for hip fracture or 20% or greater for major osteoporotic fracture

Exclusion Criteria:

  • Significant liver or kidney disease
  • Elevated prolactin level
  • Abnormal TSH
  • Abnormal 25-Vitamin D
  • PSA > 2.5
  • History of malignancy
  • Calcium > 10.6
  • Alkaline Phosphatase > 150
  • Fracture within the last 6 months
  • History of acute urinary retention
  • Hematocrit < 32% or > 50%
  • Fracture within the past 6 months
  • American Urological Association BPH symptom index > 21
  • Sleep apnea
  • Abnormalities of the esophagus which delay esophageal emptying
  • Significant cardiopulmonary disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01460654

Contact: Alexander V Uihlein, MD 617-643-9720

United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Katelyn Foley, BA    617-726-2860   
Principal Investigator: Benjamin Z Leder, MD         
Sponsors and Collaborators
Massachusetts General Hospital
Endo Pharmaceuticals
Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Benjamin Leder, MD, Associate Professor of Medicine, Massachusetts General Hospital Identifier: NCT01460654     History of Changes
Other Study ID Numbers: MGH-988
Study First Received: October 20, 2011
Last Updated: June 25, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Bone Diseases
Bone Diseases, Metabolic
Endocrine System Diseases
Gonadal Disorders
Musculoskeletal Diseases
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate
Anabolic Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Bone Density Conservation Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 25, 2014